By addressing these limitations and pursuing these future research directions, we can gain a deeper understanding of DLX6’s role in NPC and its potential as a therapeutic target, ultimately contributing to more effective treatments and improved patient outcomes. This evidence concerns the gene DLX6 and nasopharyngeal carcinoma.